Innate Pharma Cash Flow Statement (2018-2025) | IPHA

Cash Flow Statement Dec2018 Jun2019 Dec2019 Jun2020 Dec2020 Jun2021 Dec2021 Jun2022 Dec2022 Jun2023 Dec2023 Jun2024 Dec2024 Jun2025 Dec2025
Operating Activities
Net Income (Quarter) -22.98M-11.38M-75.30M7.53M-8.39M-0.08M-133.650.62M-8.14M-26.67M-52.86M-24.16M
Gains from Investment Securities (Quarter) -1.14M
Asset Writedowns and Impairment (Quarter) -51.90M-0.04M
Change in Working Capital (Quarter) -53.76M-0.36M-0.41M-0.30M-1.78M-1.36M-0.06M0.01M0.03M0.00M-0.00M
Cash from Operations (Quarter) -63.91M-61.72M-37.53M-66.87M-19.54M-12.48M-35.03M-7.37M-61.41M
Investing Activities
Capital Expenditures (Quarter) -0.83M-1.41M-0.60M-1.08M-0.29M-1.06M-0.45M-0.55M-0.34M-0.38M-0.42M-0.16M
Sales of Property, Plant and Equipment (Quarter) -0.01M0.01M
Change in Intangibles (Quarter) -72.06M-70.98M-10.25M-12.37M-0.04M-0.46M-0.60M-2.15M
Cash from Investing Activities (Quarter) -69.44M-68.76M-13.34M-15.94M-0.30M-1.05M-0.42M-0.27M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt Repayments (Quarter) -0.82M-2.19M-1.13M-2.68M-1.36M-2.37M-1.02M-2.07M-1.74M-2.54M-9.55M-10.37M
Misc.
Cash from Financing Activities (Quarter) -0.87M-1.32M-1.40M-1.48M-1.02M-1.87M-1.36M-2.12M-6.42M
Exchange Rate Effect (Quarter) -0.00M-0.01M-0.21M-0.55M-0.71M-0.44M-0.54M
Change in Cash (Quarter) -3.30M-78.58M-78.81M-39.51M-37.79M-0.86M-19.93M-13.95M-14.65M-0.00M-4.50M-44.59M
Free Cash Flow (Quarter) 0.83M1.41M-63.31M-60.64M-37.24M-65.81M0.45M-19.00M-12.15M-34.65M-6.95M-61.25M
Net Cash Flow (Quarter) -70.31M-68.76M-78.57M-79.07M-39.30M-67.92M-1.45M-21.41M-14.11M-37.15M-13.79M-61.41M